JHVEPhoto Eli Lilly (NYSE:LLY) said Friday it expects to report Q2 IPR&D pre-tax charges of around $154M, amounting to approximately $0.14 a share on a GAAP and non-GAAP basis, according to Bloomberg. Analysts were expecting Lilly to report Q2 GAAP EPS of $2.76 and non-GAAP EPS of $2.81. The drugmakerContinue Reading
jetcityimage/iStock Editorial via Getty Images Eli Lilly (NYSE:LLY) has named Gordon Brooks as its interim chief financial officer, effective July 15, 2024. Brooks has held various leadership roles during his 29-year career with the company, and currently serves as group VP, controller and corporate strategy. He will replace Anat Ashkenazi,Continue Reading
jetcityimage A new study found that patients taking Eli Lilly’s (NYSE:LLY) Mounjaro lost significantly more weight than those taking Novo Nordisk’s (NVO) Ozempic. The study, which analyzed the electronic health records of roughly 41,000 obese or overweight patients who took the drugs, found that the mean loss in body weightContinue Reading
jetcityimage/iStock Editorial via Getty Images Eli Lilly’s (NYSE:LLY) newly approved Alzheimer’s drug Kisunla could generate peak sales of up to $7.1B for the company and will help diversify the drugmaker’s revenue stream, according to BMO. Kisunla, also known as donanemab, will be priced at $32,000 per year, with each vialContinue Reading
jetcityimage/iStock Editorial via Getty Images The U.S. FDA has approved Eli Lilly’s (NYSE:LLY) donanemab as a treatment for early Alzheimer’s disease. The therapy, which is given via infusion once a month, will be marketed under the name Kisunla. Lilly noted that the treatment will cost $12,522 over six months andContinue Reading
manassanant pamai Augustine Therapeutics, focused on novel treatments for neurodegenerative and cardio metabolic diseases, Wednesday said that it has raised €17 million ($18.5 million) in the first closing of its Series A round. The financing was led by Asabys Partners, with participation from Eli Lilly and Company (NYSE:LLY), and theContinue Reading
